(Q38947183)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

review article

1 reference

title

New and emerging targeted treatments in advanced non-small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1

Fred R Hirsch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

author name string

Jacinta Wiens

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

Paul A Bunn

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

language of work or name

English

0 references

publication date

1 September 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

volume

388

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

issue

10048

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

22 March 2020

page(s)

1012-1024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

22 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

RET, ROS1 and ALK fusions in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

KIF5B-RET fusions in lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

The transcriptional landscape and mutational profile of lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Comprehensive molecular profiling of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

CD74-NRG1 fusions in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Comprehensive genomic characterization of squamous cell lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Comprehensive genomic profiles of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Scientific Advances in Lung Cancer 2015.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Surgery for NSCLC in the era of personalized medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

A combinatorial strategy for treating KRAS-mutant lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

cMET Exon 14 Skipping: From the Structure to the Clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients w

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Immune Checkpoint Blockade in Cancer Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

The future of immune checkpoint therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

Personalized therapy on the horizon for squamous cell carcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931473-8

7 January 2021

10.1016/S0140-6736(16)31473-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27598681%20AND%20SRC:MED&resulttype=core&format=json

release_7ojbnf4hpzfc7hhhibk3n67loq

22 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7ojbnf4hpzfc7hhhibk3n67loq

24 November 2022

mapped directly with Wikidata item

1 reference